RediJect Coelenterazine h Bioluminescent Substrate

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

RediJect Coelenterazine h is a bioluminescence substrate in a ready-to-use format developed by the in vivo imaging leaders to fit your laboratory workflow. With PerkinElmer’s RediJect Coelenterazine you can ensure reproducible results by minimizing variability in formulation, minimizing freeze/thaw and controlling batch to batch variation. RediJect Coelenterazine has been formulated to fit common workflow patterns and optimize results for all your experiments with Renilla luciferase. This ready-to-use substrate formulation allows you to concentrate on animal handling and biology.

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.